Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1. (Currently Amended): A[[n]] pharmaceutical composition for administration to an animal subject comprising a therapeutically effective amount of an ~~isolated~~ antisense molecule ~~comprising a nucleotide sequence~~ targeted to the sequence set forth in SEQ ID NO:1 admixed with a pharmaceutically acceptable carrier.

2. (Currently Amended): A[[n]] pharmaceutical composition for administration to an animal subject comprising a therapeutically effective amount of an ~~isolated~~ antisense molecule ~~comprising a nucleotide sequence~~ targeted to the sequence set forth in SEQ ID NO:2 admixed with a pharmaceutically acceptable carrier.

3. (Currently Amended) A[[n]] pharmaceutical composition for administration to an animal subject comprising a therapeutically effective amount of an ~~isolated~~ antisense molecule comprising the nucleotide sequence set forth in SEQ ID NO:3, said sequence complementary to nucleotides 156-185 of BC200 RNA, admixed with a pharmaceutically acceptable carrier.

4. (Currently Amended) A[[n]] pharmaceutical composition for administration to an animal subject comprising a therapeutically effective amount of an ~~isolated~~ antisense molecule comprising the nucleotide sequence set forth in SEQ ID NO:4, said sequence complementary to nucleotides 158-178 of BC200 RNA, admixed with a pharmaceutically acceptable carrier.

5. (Withdrawn) An isolated antisense molecule comprising the nucleotide sequence set forth in SEQ ID NO:5.

6. (Withdrawn) An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:6, complementary to DNA encoding BC200 RNA.

7. (cancelled).

8. (Withdrawn) A method for treating a neurological disorder or cancer in a subject, said method comprising down-regulating BC200 RNA in the subject.

9. (Withdrawn) The method of claim 8 wherein the down-regulating of BC200 RNA in a subject comprises administering a therapeutically effective amount of a dominant negative mutant of BC200 RNA or a small interfering RNA.

10. (Withdrawn) The method of claim 8 wherein the down-regulating of BC200 comprises administering a therapeutically effective amount of an antisense molecule targeted to the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

11. (Withdrawn) The method of claim 8 wherein the down-regulating of BC200 comprises administering a therapeutically effective amount of at least one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.

12. (Withdrawn) The method of any one claims 8-11 wherein the neurological disorder is at least one of Alzheimer's disease, Fragile X mental retardation syndrome, Down's syndrome and Parkinson's disease.

13. (Withdrawn) The method of any one of claims 8-11 wherein the cancer is at least one of squamous cell carcinoma of the tongue and lung, epithelial carcinoma of the esophagus, tubular adenocarcinoma of the stomach, breast adenocarcinoma, adenocarcinoma of the lung, mucoepidermoid of the partoid gland, melanoma of the skin, papillary carcinoma of the ovaries, or endothelial adenocarcinoma of the cervix.

14. (Withdrawn) A method for treating epilepsy in a subject, the method comprising up-regulating BC200 RNA in a patient.

15. (Withdrawn) The method of claim 14 wherein the up-regulating comprises administering to the patient a therapeutically effective amount of BC200 RNA.

16. (Withdrawn) The method of claim 14 wherein the up-regulating comprises administering to the patient a gene therapy construct having a DNA or RNA corresponding to BC200 operably linked to a promoter which functions in the cells of the subject.

17. (Currently Amended) A kit comprising a therapeutically effective amount of an antisense molecule for administration to an animal subject of any one of claims 1-[[6]] 4 and a pharmaceutically acceptable carrier.

18. (Currently Amended) The kit of claim 17 wherein the therapeutically effective amount of the antisense molecule for administration to an animal subject is packaged separately from the pharmaceutically acceptable carrier.

19. (Original) The kit of claim 17 wherein the antisense molecule is admixed with the pharmaceutically acceptable carrier.

20. (New) The pharmaceutical composition of any one of claims 1-4 wherein the animal subject is human.